Next Article in Journal
Special Issue “Bioinformatics of Unusual DNA and RNA Structures”
Previous Article in Journal
Melatonin Inhibits Hypoxia-Induced Alzheimer’s Disease Pathogenesis by Regulating the Amyloidogenic Pathway in Human Neuroblastoma Cells
Previous Article in Special Issue
Hesperidin as a Species-Specific Modifier of Aphid Behavior
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Puerarin—A Promising Flavonoid: Biosynthesis, Extraction Methods, Analytical Techniques, and Biological Effects

Biocatalysis Group, Department of Applied Chemistry and Engineering of Organic and Natural Compounds, Faculty of Industrial Chemistry and Environmental Engineering, Politehnica University Timisoara, Vasile Pârvan No. 6, 300223 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(10), 5222; https://doi.org/10.3390/ijms25105222
Submission received: 15 March 2024 / Revised: 26 April 2024 / Accepted: 8 May 2024 / Published: 10 May 2024

Abstract

:
Flavonoids, a variety of plant secondary metabolites, are known for their diverse biological activities. Isoflavones are a subgroup of flavonoids that have gained attention for their potential health benefits. Puerarin is one of the bioactive isoflavones found in the Kudzu root and Pueraria genus, which is widely used in alternative Chinese medicine, and has been found to be effective in treating chronic conditions like cardiovascular diseases, liver diseases, gastric diseases, respiratory diseases, diabetes, Alzheimer’s disease, and cancer. Puerarin has been extensively researched and used in both scientific and clinical studies over the past few years. The purpose of this review is to provide an up-to-date exploration of puerarin biosynthesis, the most common extraction methods, analytical techniques, and biological effects, which have the potential to provide a new perspective for medical and pharmaceutical research and development.

1. Introduction

For many centuries, various cultures have used medicinal plants to treat ailments and enhance overall health. These plants contain bioactive compounds that have therapeutic properties, making them a valuable source of medicine [1,2,3,4,5,6]. From ancient civilizations to modern times, the knowledge of medicinal plants has been passed down through generations, contributing to the development of traditional medicine systems such as Ayurveda, traditional Chinese medicine, and Native American healing practices [7].
The popularity of medicinal plants has increased recently due to their natural origin and their potential to have fewer side effects than compounds from synthetic origin [8,9,10]. As a result, extensive research is being conducted to identify and understand the bioactive compounds in these plants, leading to the development of new pharmaceuticals and nutraceuticals [9,11,12].
Today, a significant number of pharmaceutical drugs come from plants or are inspired by the bioactive compounds found in medicinal plants. Flavonoids and phenolic compounds are just some of the many plant secondary metabolites that can be included in bioactive compounds [13,14]. They have the ability to treat numerous health conditions, such as respiratory disorders, digestive problems, skin problems, and chronic diseases like diabetes and cardiovascular conditions [15,16,17].
Flavonoids have received significant attention in nutrition, the medical field, and pharmaceutical research due to their health-promoting effects. Flavonoids are a class of polyphenolic compounds found in various fruits, vegetables, different microorganisms, and medicinal plants [17,18,19]. The diversity of flavonoids in nature and their promising bioactivities make them promising candidates for developing novel therapeutic agents. Their biological activities, which include antioxidant, anti-inflammatory, antiviral, anti-cancer, and antimicrobial properties, have earned them their reputation [17]. Furthermore, flavonoids and other bioactive compounds present in medicinal plants can be used to enhance their therapeutic potential through synergistic effects [20]. Flavanones, flavones, isoflavones, flavonols, flavanols, and anthocyanins are among the subclasses that they further classify into, with each having specific biological effects [17,21,22]. The focus of research studies is now on discovering, extracting, and isolating new plant molecules that have various biological effects, including various high-potential isoflavones.
Plant-derived flavonoids known as phytoestrogens are isoflavones, which have structural similarities to the hormone estrogen [23,24,25]. Their natural abundance is present in soybeans and other legumes, and they have been investigated for their potential health benefits [25,26,27]. Due to their potential to have both estrogenic and antiestrogen effects in the body, the phytochemistry of isoflavones is gaining much attention. Their dual biological effects are due to their ability to bind to estrogen receptors, mimicking estrogen’s actions in certain tissues while blocking its effects in others [24,27]. The most common isoflavones are genistein, daidzein, glycitein, and formononetin (Figure 1).
Recently, one of the isoflavones that were discovered has revealed significant therapeutic potential for both the pharmaceutical industry and the entire scientific medical world.
Puerarin, also known as daidzein-8-C-glucoside, is found in the roots of the kudzu plant and the genus Pueraria [28,29,30]. The kudzu plant has compounds like flavonoids, saponins, xanthones, lignans, sterols, and other compounds. The genus Pueraria is identified by puerarin, an isoflavone that is used as its chemotaxonomic marker. Isoflavone glycosides, particularly puerarin, are responsible for many of the genus Pueraria bioactivities [30]. At positions 7 and 4’, there are hydroxy group substitutions, and at position 8, it is accompanied by a beta-D-glucopyranosyl residue through a C-glycosidin linkage (Figure 2). To develop new applications and improve its bioavailability, it is essential to comprehend the biosynthesis pathway of puerarin.
This review aims to explore the biosynthesis pathway, extraction methods, analytical techniques, and provide a comprehensive summary of the biological effects of puerarin.

2. Biosynthesis of Puerarin

Isoflavones are derivatives of flavonoids, which are derivatives of 2-phenyl-benzo-γ-pyrone (2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one). They are included in the large family of natural polyphenolic compounds with structure type C3-C6-C3 [17,31].
Several enzymes and key reactions are involved in the puerarin biosynthesis pathway, which starts with the shikimate pathway. Chorismic acid is formed as the end product of the shikimate pathway after aldol condensation reactions between phosphoenolpyruvic acid and D-erythrose 4-phosphate [17,31]. The enzymes prephenate-aminotransferase (PhAT) and arrogate-dehydratase (ADT) are responsible for converting this into the amino acid phenylalanine. After the formation of the amino acid phenylalanine, biosynthesis occurs through the phenylpropanoid pathway. The deamination of phenylalanine to form trans-cinnamic acid occurs in the presence of phenylalanine-ammonia liase (PhaAL) [17,32]. The 4-coumaric acid is converted from trans-cinnamic acid by cinnamate-4-hydroxylase (C4L). Providing the compound 4-coumaroyl-CoA will be achieved by using 4-coumarate-CoA-ligase (C4CoAL) [17,31,32]. Afterwards, 4-coumaroyl-CoA is converted to isoliquiritigenin by chalcone synthase and chalcone reductase [33,34,35,36,37,38]. Chalcone isomerase (CHI) then catalyzes the formation of liquiritigenin from isoliquiritigenin, which is further catalyzed by 2-hydroxyisoflavanone (IFS) to produce 2,7,4′-trihydroxyisoflavonone [36,37,39].
Two different pathways allow for the production of puerarin through the catalysis of the chalcone isoflavone, by (i) 2-hydroxyisoflavanone dehydratase (HID) to form daidzein, and by (ii) 8-C-glucosyltransferase (8-C-GT) to form trihydroxyisoflavonone-8-C-glucoside (Figure 3) [35,36]. The transformation of it into puerarin is accomplished by PlUGT43 through 8-C-glucosylation. The 8-C-glycosylation reaction during the biosynthesis of puerarin is still being debated [37,40].

3. Extraction Methods and Analytical Techniques

Puerarin can be found in several natural sources, such as Kudzu root (Pueraria lobata), a traditional medicinal legume taxon native to Southeast Asia, which has a wide range of species and can be found in China [41,42,43]. Additionally, puerarin can also be found in other plants belonging to the genus Pueraria [41,42,44,45]. Puerarin can be obtained for various applications using these natural sources in a sustainable and environmentally friendly way.
There are several methods for extracting puerarin from Kudzu root, including the following: (i) solvent extraction; (ii) ultrasound extraction; (iii) enzyme-assisted extraction; (iv) microwave-assisted extraction [46]. Choosing the right extraction method for isoflavones requires considering factors like efficiency, cost, and environmental impact, as each method has its own advantages and disadvantages [17,47,48].
Despite its simplicity and cost-effectiveness, solid-liquid extraction is a traditional method that may not achieve the highest purity of puerarin. Supercritical fluid extraction is a method that offers high purity and efficiency, but it can be expensive and complex to set up [49]. Microwave-assisted extraction can enhance efficiency by accelerating the ex-traction process and reducing extraction time. Using microwave energy can lead to an increase in operational costs [50]. Besides these methods, there have been attempts to extract puerarin using other extraction methods, such as ultrasound-assisted extraction and enzymatic extraction [46].
He Zhu et al. conducted a study to evaluate how differences in ultrasonic power, microwave power, and time affect the rate of flavonoid extraction from Kudzu root samples. Their research revealed that flavonoid extract yield was increased by increasing ultrasonic and microwave power. Microwave power, followed by ultrasonic time and power, were found to be the most effective combination factors for influencing the flavonoid extraction rate [51].
Duru et al.’s investigation involved evaluating how well isoflavones (daidzein, genistein, puerarin) are extracted from the by-products of Kudzu roots using natural deep eutectic solvents coupled with ultrasound-supported extraction. The use of natural deep eutectic solvents coupled with ultrasound-assisted extraction was evaluated against the usual Soxhlet extraction technique, and the amounts of the extracted isoflavones were determined by HPLC-UV/VIS. The results of this study suggest that the developed technique may have advantages such as reduced extraction time and the use of inexpensive and green extraction solvents, but further investigation is needed to fully optimize the conditions for extracting isoflavones [52]. Below, the most commonly used extraction techniques are presented with different advantages and disadvantages (Table 1).
In summary, different extraction methods, including ultrasound-assisted extraction, supercritical fluid extraction, enzyme-assisted extraction, microwave-assisted extraction, and deep eutectic solvents extraction, provide distinct advantages in the extraction of puerarin from Kudzu root or other plants of the genus Pueraria [46]. Various factors affect the extraction of plant sources, including the type of plant material, solvent selection, extraction technique, and operating conditions [47,68].
Understanding these key factors is necessary to optimize the extraction process and achieve high yields with desired properties. The primary variable in any extraction method is definitely the solvent selection. It is important to choose the extraction solvent based on its solubility and the intensity of interactions with the matrix. To examine the solvent’s properties, it is necessary to pay attention to polarity, pH, viscosity, surface tension, vapor pressure, boiling point, solid–liquid ratio, as well as the effect on the purity and activity of the extracted compound [68].
For example, in the case of ultrasound-assisted extraction, at the adjusted temperature, a solvent with low vapor pressure facilitates cavitation, which increases the impact of ultrasound on the process, and on the other hand viscous solutions have the opposite effect, increasing the amplitude of waves, hindering the propagation of ultrasound, and producing mechanical effects on the sample due to cavitation [68,69]. The frequency of extraction is a crucial parameter that prevents the cavitation process from fully occurring and decreases the size of bubbles by decreasing their expansion time [69]. The dielectric constant and the dissipation factor are crucial parameters for microwave-assisted extraction, and modifying the dielectric constant is necessary to obtain suitable characteristics. More microwave energy is required for high volumes of solvent because microwave radiation is absorbed by the solvent [68,70]. Very high microwave power can lead to lower yields, which can be attributed to the heat generated by the microwave energy causing the disintegration and thermal degradation of the puerarin content.
The potential of these advanced techniques in improving extraction efficiency, reducing processing time, and enhancing the quality of extracted puerarin is significant. Additionally, these extraction methods can also integrate green solvents and environmentally friendly approaches, which promote sustainability and align with the industry’s growing demand for chemical-free and eco-friendly processes, according to the basics and fundamentals of green chemistry [71,72].
Analytical techniques are crucial for the pharmaceutical industry, as they aid in comprehending the physical and chemical stability of the bioactive compound, which influences the selection and design of the dosage form, assesses stability, and identifies the impurities [73]. To determine the presence and concentration of puerarin, various analytical methods can be employed. Spectroscopic methods such as UV-VIS spectrophotometry and mass spectrometry are included, along with chromatographic techniques such as high-performance liquid chromatography and gas chromatography [74,75].
One of the commonly used methods for the analysis of puerarin is high-performance liquid chromatography (HPLC) [76,77,78]. HPLC is a popular technique for estimating puerarin concentration because it allows for the separation and quantification of individual components in a sample. Choosing an analytical method for puerarin determination necessitates considering factors like sensitivity, selectivity, and reproducibility. The accuracy and precision of the results can only be guaranteed by verifying the chosen method through standardization and calibration [76,79].
Even though high-performance liquid chromatography and mass spectrometry are widely used for analyzing puerarin, it is essential to critically evaluate the limitations and potential drawbacks that arise with these approaches. Depending on the cost of the equipment and the specialized training needed for the operation, accessibility can be limited [79]. In addition to the analytical methods mentioned, nuclear magnetic resonance (NMR) spectroscopy is another effective method for analyzing puerarin. The identification and quantification of puerarin in complex samples, such as plant extracts, can be achieved through NMR spectroscopy, which provides detailed information about the molecular structure and dynamics of compounds. For example, Yi et al. performed a complete NMR analysis of puerarin and explored the antioxidative activity by bond dissociation enthalpy (BDE) calculations. Their results revealed that in methanol-d4, the PBE0/aug-cc-pVTZ approach was employed to calculate the root mean square value of puerarin to 5.73 ppm. Also, they calculated the 13C and 1H chemical shifts of the puerarin molecule (in C7 and C4’ positions) in methanol-d4, phenolic O–H bond dissociation enthalpies (84.3 kcal·mol−1; 82.5 kcal·mol−1), and single-step hydrogen atom transfer [80].
Integrating NMR analysis with other analytical techniques (e.g., HPLC, MS) can lead to a more comprehensive assessment of bioactive molecules, which allows researchers to take advantage of the strengths of both methods while minimizing their limitations [81,82,83]. Furthermore, these analytical methods offer precise information about the molecular structure of puerarin, which makes it easier to identify and quantify complex samples (Table 2).

4. Biological Effects of Puerarin

Chronic diseases are becoming more prevalent as a result of the increasing ill population worldwide, leading to a serious threat to the health of individuals. Although new drugs are being developed to improve health, there has been insufficient progress in this area.
Plant-derived natural preparations have become a valuable resource for the development of new drugs. Bioactive molecules from Chinese herbal medicines (e.g., ginseng, astragalus, Ginkgo biloba) have been discovered to have ‘life-nourishing’ properties, and their role in health is being more and more recognized [91,92,93].
Puerarin has also gained recognition over the years due to its diverse pharmacological and biological effects in the treatment of acute and chronic diseases [28,94,95,96,97,98], such as cardiovascular diseases [99,100,101,102], liver diseases [103,104,105], neurologic disorders [26,106,107], respiratory diseases [108], and many more.
The structure–activity relationship of puerarin has been the subject of numerous studies conducted by researchers in recent decades. Analyzing the relationship between the structure and activity of puerarin allows us to develop more effective analogues that can highlight more pronounced biological effects, particularly in oncological drug development. Discovering new biological effects is also a focus of current research. Current research also focuses on the discovery of new biological effects. The development of an active pharmaceutical form in which puerarin is encapsulated has been the focus of fewer clinical studies. Besides discovering new biological effects, it is also essential to monitor the potential adverse effects that may occur.
In the forthcoming section, we summarize an analysis of the biological effects of puerarin (Table 3).

5. Future Perspectives

Pueraria species have been employed in China to treat a range of illnesses for thousands of years. Numerous impressive achievements have been made and more studies have been conducted in recent decades. Biotechnology has led to the development of new extraction methods that can extract and isolate more biologically active components from medicinal plants, which has resulted in the introduction of drugs into clinics or supplements for the pharmaceutical market.
Puerarin, which is an active ingredient in traditional herbal medicine, has been acknowledged to possess a variety of biological effects. Numerous studies are beginning to find solutions to the issues that require puerarin to be used as a therapeutic agent, such as its limited bioavailability caused by its low solubility and lipid stability.
It is undeniable that biotechnology is a tool for achieving sustainable processes and products. The specificity, activity, and stability of enzymes are expected to be expanded in green chemistry and biotechnology as a result of advances in enzyme engineering and biocatalyst optimization. The demand for eco-friendly and cost-effective synthetic routes, particularly for addressing puerarin issues, will make enzymatic synthesis a key factor in innovation and progress in the years ahead [141]. Furthermore, enzymatic synthesis will be enhanced by applying advanced computational tools and machine learning algorithms to design and optimize enzymes for specific synthesis pathways for different drugs or natural compounds, such as puerarin [142,143].
As the field of enzymatic synthesis progresses, there are several emerging trends that could revolutionize the production and use of nanoparticles. Metal nanoparticles, solid lipid nanoparticles, nanomicelles, cyclodextrins, dendrimers, and nano-vesicle systems are among the most common nanoparticles that have been studied for their biocompatibility and biodegradability [144,145,146]. The encapsulation of various nanoparticles with puerarin has been carried out by researchers for many years to improve its bioavailability and therapeutic effects, and the results have been promising [147,148,149,150]. Enzymatic synthesis and nanoparticle production have immense potential due to ongoing research and innovation, which will lead to more efficient, sustainable, and versatile manufacturing processes.
This review provides a preliminary up-to-date overview of puerarin’s biosynthesis, extraction methods, analytical techniques, and bioactivities, with emphasis on its potential as a bioactive molecule in the treatment of various systemic diseases. As this field’s research progresses, it is evident that the development of innovative extraction techniques will have a significant impact on improving the production and utilization of puerarin in pharmaceuticals, food supplements, and other related products. With more in-depth experimental and clinical studies on puerarin, its biological activity mechanism will be more fully revealed, the types of medication will be more varied, and the clinical indications will be expanded in the future.

Author Contributions

Conceptualization, methodology, validation, writing—original draft preparation, writing—review and editing, visualization, and supervision: S.L.; conceptualization, validation, writing—review and editing, and visualization: C.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Moses, T.; Goossens, A. Plants for Human Health: Greening Biotechnology and Synthetic Biology. J. Exp. Bot. 2017, 68, 4009–4011. [Google Scholar] [CrossRef] [PubMed]
  2. Schaal, B. Plants and People: Our Shared History and Future. Plants People Planet 2019, 1, 14–19. [Google Scholar] [CrossRef]
  3. Chaachouay, N.; Zidane, L. Plant-Derived Natural Products: A Source for Drug Discovery and Development. Drugs Drug Candidates 2024, 3, 184–207. [Google Scholar] [CrossRef]
  4. Pergola, M.; De Falco, E.; Belliggiano, A.; Ievoli, C. The Most Relevant Socio-Economic Aspects of Medicinal and Aromatic Plants through a Literature Review. Agriculture 2024, 14, 405. [Google Scholar] [CrossRef]
  5. Carrubba, A.; Marceddu, R.; Sarno, M. Bringing Spontaneous Plants to Cultivation: Issues and Constraints for Medicinal and Aromatic Plants. In Proceedings of the XXXI International Horticultural Congress (IHC2022): International Symposium on Medicinal and Aromatic Plants: Domestication, Breeding, Cultivation and New Perspectives, Angers, France, 14–20 August 2022; Volume 1358, pp. 43–48. [Google Scholar]
  6. Ansari, M.K.A.; Iqbal, M.; Chaachouay, N.; Ansari, A.A.; Owens, G. The Concept and Status of Medicinal and Aromatic Plants: History, Pharmacognosy, Ecology, and Conservation. In Plants as Medicine and Aromatics; CRC Press: Boca Raton, FL, USA, 2023; pp. 129–144. [Google Scholar]
  7. Azaizeh, H.; Saad, B.; Cooper, E.; Said, O. Traditional Arabic and Islamic Medicine, a Re-Emerging Health Aid. Evid.-Based Complement. Altern. Med. 2010, 7, 340679. [Google Scholar] [CrossRef]
  8. Hamilton, A.C. Medicinal Plants, Conservation and Livelihoods. Biodivers. Conserv. 2004, 13, 1477–1517. [Google Scholar] [CrossRef]
  9. Woo, S.; Marquez, L.; Crandall, W.J.; Risener, C.J.; Quave, C.L. Recent Advances in the Discovery of Plant-Derived Antimicrobial Natural Products to Combat Antimicrobial Resistant Pathogens: Insights from 2018–2022. Nat. Prod. Rep. 2023, 40, 1271–1290. [Google Scholar] [CrossRef]
  10. Yu, J.; Zheng, Y.; Song, C.; Chen, S. New Insights into the Roles of Fungi and Bacteria in the Development of Medicinal Plant. J. Adv. Res. 2024, in press. [CrossRef] [PubMed]
  11. Hui, Z.; Wen, H.; Zhu, J.; Deng, H.; Jiang, X.; Ye, X.Y.; Wang, L.; Xie, T.; Bai, R. Discovery of Plant-Derived Anti-Tumor Natural Products: Potential Leads for Anti-Tumor Drug Discovery. Bioorg Chem. 2024, 142, 106957. [Google Scholar] [CrossRef]
  12. Peterle, L.; Sanfilippo, S.; Borgia, F.; Li Pomi, F.; Vadalà, R.; Costa, R.; Cicero, N.; Gangemi, S. The Role of Nutraceuticals and Functional Foods in Skin Cancer: Mechanisms and Therapeutic Potential. Foods 2023, 12, 2629. [Google Scholar] [CrossRef]
  13. Phillipson, J.D. Phytochemistry and Pharmacognosy. Phytochemistry 2007, 68, 2960–2972. [Google Scholar] [CrossRef] [PubMed]
  14. Teoh, E.S. Secondary Metabolites of Plants. In Medicinal Orchids of Asia; Springer International Publishing: Berlin/Heidelberg, Germany, 2016; pp. 59–73. [Google Scholar]
  15. Zhao, J.H.; Wang, Y.W.; Yang, J.; Tong, Z.J.; Wu, J.Z.; Wang, Y.B.; Wang, Q.X.; Li, Q.Q.; Yu, Y.C.; Leng, X.J.; et al. Natural Products as Potential Lead Compounds to Develop New Antiviral Drugs over the Past Decade. Eur. J. Med. Chem. 2023, 260, 115726. [Google Scholar] [CrossRef] [PubMed]
  16. Chen, X.; Lan, W.; Xie, J. Natural Phenolic Compounds: Antimicrobial Properties, Antimicrobial Mechanisms, and Potential Utilization in the Preservation of Aquatic Products. Food Chem. 2024, 440, 138198. [Google Scholar] [CrossRef] [PubMed]
  17. Liga, S.; Paul, C.; Péter, F. Flavonoids: Overview of Biosynthesis, Biological Activity, and Current Extraction Techniques. Plants 2023, 12, 2732. [Google Scholar] [CrossRef] [PubMed]
  18. Lv, J.; Yang, S.; Zhou, W.; Liu, Z.; Tan, J.; Wei, M. Microbial Regulation of Plant Secondary Metabolites: Impact, Mechanisms and Prospects. Microbiol. Res. 2024, 283, 127688. [Google Scholar] [CrossRef]
  19. Su, Y.; Wang, J.; Gao, W.; Wang, R.; Yang, W.; Zhang, H.; Huang, L.; Guo, L. Dynamic Metabolites: A Bridge between Plants and Microbes. Sci. Total Environ. 2023, 899, 165612. [Google Scholar] [CrossRef]
  20. Wrońska, N.; Szlaur, M.; Zawadzka, K.; Lisowska, K. The Synergistic Effect of Triterpenoids and Flavonoids—New Approaches for Treating Bacterial Infections? Molecules 2022, 27, 847. [Google Scholar] [CrossRef] [PubMed]
  21. Pietta, P.; Minoggio, M.; Bramati, L. Plant Polyphenols: Structure, Occurrence and Bioactivity. In Studies in Natural Products Chemistry; Rahman, A., Ed.; Elsevier: Amsterdam, The Netherlands, 2003; Volume 28, pp. 257–312. ISBN 1572-5995. [Google Scholar]
  22. Chen, S.; Wang, X.; Cheng, Y.; Gao, H.; Chen, X. A Review of Classification, Biosynthesis, Biological Activities and Potential Applications of Flavonoids. Molecules 2023, 28, 4982. [Google Scholar] [CrossRef]
  23. Alexander, V.S. Phytoestrogens and Their Effects. Eur. J. Pharmacol. 2014, 741, 230–236. [Google Scholar]
  24. Křížová, L.; Dadáková, K.; Kašparovská, J.; Kašparovský, T. Isoflavones. Molecules 2019, 24, 1076. [Google Scholar] [CrossRef]
  25. Tan, S.T.; Tan, S.S.; Tan, C.X. Soy Protein, Bioactive Peptides, and Isoflavones: A Review of Their Safety and Health Benefits. PharmaNutrition 2023, 25, 100352. [Google Scholar] [CrossRef]
  26. Ren, Y.; Qu, S. Constituent Isoflavones of Puerariae radix as a Potential Neuroprotector in Cognitive Impairment: Evidence from Preclinical Studies. Ageing Res. Rev. 2023, 90, 102040. [Google Scholar] [CrossRef] [PubMed]
  27. Gómez-Zorita, S.; González-Arceo, M.; Fernández-Quintela, A.; Eseberri, I.; Trepiana, J.; Portillo, M.P. Scientific Evidence Supporting the Beneficial Effects of Isoflavones on Human Health. Nutrients 2020, 12, 3853. [Google Scholar] [CrossRef] [PubMed]
  28. Zhou, Y.-X.; Zhang, H.; Peng, C. Puerarin: A Review of Pharmacological Effects. Phytother. Res. 2014, 28, 961–975. [Google Scholar] [CrossRef] [PubMed]
  29. Esch, H.L.; Kleider, C.; Scheffler, A.; Lehmann, L. Chapter 34—Isoflavones: Toxicological Aspects and Efficacy. In Nutraceuticals; Gupta, R.C., Ed.; Academic Press: Boston, MA, USA, 2016; pp. 465–487. ISBN 978-0-12-802147-7. [Google Scholar]
  30. Bacanlı, M.; Aydın, S.; Başaran, A.A.; Başaran, N. Chapter 33—A Phytoestrogen Puerarin and Its Health Effects. In Polyphenols: Prevention and Treatment of Human Disease, 2nd ed.; Watson, R.R., Preedy, V.R., Zibadi, S., Eds.; Academic Press: Cambridge, MA, USA, 2018; pp. 425–431. ISBN 978-0-12-813008-7. [Google Scholar]
  31. Dias, M.C.; Pinto, D.C.G.A.; Silva, A.M.S. Plant Flavonoids: Chemical Characteristics and Biological Activity. Molecules 2021, 26, 5377. [Google Scholar] [CrossRef] [PubMed]
  32. Tariq, H.; Asif, S.; Andleeb, A.; Hano, C.; Abbasi, B.H. Flavonoid Production: Current Trends in Plant Metabolic Engineering and De Novo Microbial Production. Metabolites 2023, 13, 124. [Google Scholar] [CrossRef] [PubMed]
  33. Han, R.; Takahashi, H.; Nakamura, M.; Yoshimoto, N.; Suzuki, H.; Shibata, D.; Yamazaki, M.; Saito, K. Transcriptomic Landscape of Pueraria Lobata Demonstrates Potential for Phytochemical Study. Front. Plant Sci. 2015, 6, 426. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, X.; Li, C.; Zhou, C.; Li, J.; Zhang, Y. Molecular Characterization of the C-Glucosylation for Puerarin Biosynthesis in Pueraria Lobata. Plant J. 2017, 90, 535–546. [Google Scholar] [CrossRef] [PubMed]
  35. Cheng, H.; Huang, X.; Wu, S.; Wang, S.; Rao, S.; Li, L.; Cheng, S.; Li, L. Chromosome-Level Genome Assembly and Multi-Omics Dataset Provide Insights into Isoflavone and Puerarin Biosynthesis in Pueraria Lobata (Wild.) Ohwi. Biomolecules 2022, 12, 1731. [Google Scholar] [CrossRef] [PubMed]
  36. Xi, H.; Zhu, Y.; Sun, W.; Tang, N.; Xu, Z.; Shang, X.; Zhang, Y.; Yan, H.; Li, C. Comparative Transcriptome Analysis of Pueraria Lobata Provides Candidate Genes Involved in Puerarin Biosynthesis and Its Regulation. Biomolecules 2023, 13, 170. [Google Scholar] [CrossRef]
  37. Hu, X.; Zhu, T.; Min, X.; He, J.; Hou, C.; Liu, X. Integrated Metabolomic and Transcriptomic Analysis of Puerarin Biosynthesis in Pueraria Montana Var. Thomsonii at Different Growth Stages. Genes 2023, 14, 2230. [Google Scholar] [CrossRef] [PubMed]
  38. Maciejewska-Turska, M.; Sieniawska, E. Puerarin: Advances on Resources, Biosynthesis Pathway, Bioavailability, Bioactivity, and Pharmacology. In Handbook of Dietary Flavonoids; Xiao, J., Ed.; Springer International Publishing: Cham, Switzerland, 2023; pp. 1–30. ISBN 978-3-030-94753-8. [Google Scholar]
  39. Li, C.; Zhang, Y. Glycosylation and Methylation in the Biosynthesis of Isoflavonoids in Pueraria Lobata. Front. Plant Sci. 2023, 14, 1330586. [Google Scholar] [CrossRef] [PubMed]
  40. Adolfo, L.M.; Burks, D.; Rao, X.; Alvarez-Hernandez, A.; Dixon, R.A. Evaluation of Pathways to the C-Glycosyl Isoflavone Puerarin in Roots of Kudzu (Pueraria Montana Lobata). Plant Direct 2022, 6, e442. [Google Scholar] [CrossRef]
  41. Tungmunnithum, D.; Intharuksa, A.; Sasaki, Y. A Promising View of Kudzu Plant, Pueraria Montana Var. Lobata (Willd.) Sanjappa & Pradeep: Flavonoid Phytochemical Compounds, Taxonomic Data, Traditional Uses and Potential Biological Activities for Future Cosmetic Application. Cosmetics 2020, 7, 12. [Google Scholar] [CrossRef]
  42. Kato-Noguchi, H. The Impact and Invasive Mechanisms of Pueraria Montana Var. Lobata, One of the World’s Worst Alien Species. Plants 2023, 12, 3066. [Google Scholar] [CrossRef] [PubMed]
  43. Chen, K.; Wei, P.; Jia, M.; Wang, L.; Li, Z.; Zhang, Z.; Liu, Y.; Shi, L. Research Progress in Modifications, Bioactivities, and Applications of Medicine and Food Homologous Plant Starch. Foods 2024, 13, 558. [Google Scholar] [CrossRef] [PubMed]
  44. Bharti, R.; Chopra, B.S.; Raut, S.; Khatri, N. Pueraria tuberosa: A Review on Traditional Uses, Pharmacology, and Phytochemistry. Front. Pharmacol. 2021, 11, 582506. [Google Scholar] [CrossRef] [PubMed]
  45. Fu, M.; Jahan, M.S.; Tang, K.; Jiang, S.; Guo, J.; Luo, S.; Luo, W.; Li, G. Comparative Analysis of the Medicinal and Nutritional Components of Different Varieties of Pueraria Thomsonii and Pueraria Lobata. Front. Plant Sci. 2023, 14, 1115782. [Google Scholar] [CrossRef] [PubMed]
  46. Xuan, T.; Liu, Y.; Liu, R.; Liu, S.; Han, J.; Bai, X.; Wu, J.; Fan, R. Advances in Extraction, Purification, and Analysis Techniques of the Main Components of Kudzu Root: A Comprehensive Review. Molecules 2023, 28, 6577. [Google Scholar] [CrossRef]
  47. Tzanova, M.; Atanasov, V.; Yaneva, Z.; Ivanova, D.; Dinev, T. Selectivity of Current Extraction Techniques for Flavonoids from Plant Materials. Processes 2020, 8, 1222. [Google Scholar] [CrossRef]
  48. Chávez-González, M.L.; Sepúlveda, L.; Verma, D.K.; Luna-García, H.A.; Rodríguez-Durán, L.V.; Ilina, A.; Aguilar, C.N. Conventional and Emerging Extraction Processes of Flavonoids. Processes 2020, 8, 434. [Google Scholar] [CrossRef]
  49. Abhari, K.; Mousavi Khaneghah, A. Alternative Extraction Techniques to Obtain, Isolate and Purify Proteins and Bioactive from Aquaculture and by-Products. In Advances in Food and Nutrition Research; Academic Press Inc.: Cambridge, MA, USA, 2020; Volume 92, pp. 35–52. [Google Scholar]
  50. Bagade, S.B.; Patil, M. Recent Advances in Microwave Assisted Extraction of Bioactive Compounds from Complex Herbal Samples: A Review. Crit. Rev. Anal. Chem. 2021, 51, 138–149. [Google Scholar] [CrossRef]
  51. Zhu, H.; Xing, Y.; Akan, O.D.; Yang, T. Ultrafine Comminution-Assisted Ultrasonic-Microwave Synergistic Extraction of Pueraria Mirifica (Kudzu Flower and Root) Flavonoids. Heliyon 2023, 9, e21137. [Google Scholar] [CrossRef] [PubMed]
  52. Duru, K.C.; Slesarev, G.P.; Aboushanab, S.A.; Kovalev, I.S.; Zeidler, D.M.; Kovaleva, E.G.; Bhat, R. An Eco-Friendly Approach to Enhance the Extraction and Recovery Efficiency of Isoflavones from Kudzu Roots and Soy Molasses Wastes Using Ultrasound-Assisted Extraction with Natural Deep Eutectic Solvents (NADES). Ind. Crops Prod. 2022, 182, 114886. [Google Scholar] [CrossRef]
  53. Blicharski, T.; Oniszczuk, A. Extraction Methods for the Isolation of Isoflavonoids from Plant Material. Open Chem. 2017, 15, 34–45. [Google Scholar] [CrossRef]
  54. Zhang, Y.; Han, L.; Zou, L.; Zhang, M.; Chi, R. Development of an SVR Model for Microwave-Assisted Aqueous Two-Phase Extraction of Isoflavonoids from Radix Puerariae. Chem. Eng. Commun. 2021, 208, 1005–1016. [Google Scholar] [CrossRef]
  55. Liu, Y.-K.; Yan, E.; Zhan, H.-Y.; Zhang, Z.-Q. Response Surface Optimization of Microwave-Assisted Extraction for HPLC-Fluorescence Determination of Puerarin and Daidzein in Radix Puerariae thomsonii. J. Pharm. Anal. 2011, 1, 13–19. [Google Scholar] [CrossRef] [PubMed]
  56. Nour, A.H.; Oluwaseun, A.R.; Nour, A.H.; Omer, M.S.; Ahmed, N. Microwave-Assisted Extraction of Bioactive Compounds (Review). In Microwave Heating; Churyumov, G.I., Ed.; IntechOpen: Rijeka, Croatia, 2021; pp. 1–31. ISBN 978-1-83968-227-8. [Google Scholar]
  57. Zou, Y.; Tian, M.; Liu, C. Optimization of Ultrasound-Assisted Extraction of Puerarin from Pueraria Lobata Dried Root. J. Food Process Preserv. 2016, 40, 431–436. [Google Scholar] [CrossRef]
  58. Zheng, X.; Chen, J.; Jiang, X.; Guo, Q. Ultrasonic-Assisted Extraction of Puerarin Optimized by Response Surface Methodology. In Proceedings of the 2015 Chinese Intelligent Automation Conference, Fuzhou, China, 30 March 2015; Deng, Z., Li, H., Eds.; Springer: Berlin/Heidelberg, Germany, 2015; pp. 499–508. [Google Scholar]
  59. Aihua, S.; Xiaoyan, C.; Xiaoguang, Y.; Jiang, F.; Yanmin, L.; Zhou, J. Applications and Prospects of Ultrasound-Assisted Extraction in Chinese Herbal Medicine. Open Access J. Biomed. Sci. 2019, 1. [Google Scholar] [CrossRef]
  60. Zeng, X.; Tan, H.; Liu, B.; Wen, Y. Optimization of Ultrasonic-Assisted Extraction and Purification of Total Flavonoids with Biological Activities from Radix Puerariae. Biomass Convers. Biorefin 2023. [Google Scholar] [CrossRef]
  61. Vinitha, U.G.; Sathasivam, R.; Muthuraman, M.S.; Park, S.U. Intensification of Supercritical Fluid in the Extraction of Flavonoids: A Comprehensive Review. Physiol. Mol. Plant Pathol. 2022, 118, 101815. [Google Scholar] [CrossRef]
  62. Khaw, K.Y.; Parat, M.O.; Shaw, P.N.; Falconer, J.R. Solvent Supercritical Fluid Technologies to Extract Bioactive Compounds from Natural Sources: A Review. Molecules 2017, 22, 1186. [Google Scholar] [CrossRef] [PubMed]
  63. Majik, M.S.; Gawas, U.B. Chapter 2—Recent Advances in Extraction of Natural Compounds. In New Horizons in Natural Compound Research; Meena, S.N., Nandre, V., Kodam, K., Meena, R.S., Eds.; Academic Press: Cambridge, MA, USA, 2023; pp. 17–33. ISBN 978-0-443-15232-0. [Google Scholar]
  64. Huang, Y.; Yang, J.; Zhao, Y.; Yu, L.; He, Y.; Wan, H.; Li, C. Screening, Optimization, and Bioavailability Research of Natural Deep Eutectic Solvent Extracts from Radix Pueraria. Molecules 2021, 26, 729. [Google Scholar] [CrossRef]
  65. Makkliang, F.; Siriwarin, B.; Yusakul, G.; Phaisan, S.; Sakdamas, A.; Chuphol, N.; Putalun, W.; Sakamoto, S. Biocompatible Natural Deep Eutectic Solvent-Based Extraction and Cellulolytic Enzyme-Mediated Transformation of Pueraria Mirifica Isoflavones: A Sustainable Approach for Increasing Health-Bioactive Constituents. Bioresour. Bioprocess. 2021, 8, 76. [Google Scholar] [CrossRef] [PubMed]
  66. Wang, T.; Guo, Q.; Yang, H.; Gao, W.; Li, P. PH-Controlled Reversible Deep-Eutectic Solvent Based Enzyme System for Simultaneous Extraction and in-Situ Separation of Isoflavones from Pueraria Lobata. Sep. Purif. Technol. 2022, 292, 120992. [Google Scholar] [CrossRef]
  67. Kaoui, S.; Chebli, B.; Zaidouni, S.; Basaid, K.; Mir, Y. Deep Eutectic Solvents as Sustainable Extraction Media for Plants and Food Samples: A Review. Sustain. Chem. Pharm. 2023, 31, 100937. [Google Scholar] [CrossRef]
  68. Chaves, J.O.; de Souza, M.C.; da Silva, L.C.; Lachos-Perez, D.; Torres-Mayanga, P.C.; Machado, A.P.d.F.; Forster-Carneiro, T.; Vázquez-Espinosa, M.; González-de-Peredo, A.V.; Barbero, G.F.; et al. Extraction of Flavonoids From Natural Sources Using Modern Techniques. Front. Chem. 2020, 8, 507887. [Google Scholar] [CrossRef] [PubMed]
  69. Jurinjak Tušek, A.; Šamec, D.; Šalić, A. Modern Techniques for Flavonoid Extraction—To Optimize or Not to Optimize? Appl. Sci. 2022, 12, 11865. [Google Scholar] [CrossRef]
  70. Routray, W.; Orsat, V. Microwave-Assisted Extraction of Flavonoids: A Review. Food Bioprocess Technol. 2012, 5, 409–424. [Google Scholar] [CrossRef]
  71. Ameta, S.C.; Ameta, R. Green Chemistry: Fundamentals and Applications; CRC Press: Boca Raton, FL, USA, 2023; ISBN 1000932648. [Google Scholar]
  72. Medina Valderrama, C.J.; Morales Huamán, H.I.; Valencia-Arias, A.; Vasquez Coronado, M.H.; Cardona-Acevedo, S.; Delgado-Caramutti, J. Trends in Green Chemistry Research between 2012 and 2022: Current Trends and Research Agenda. Sustainability 2023, 15, 13946. [Google Scholar] [CrossRef]
  73. Singh, D.; Isharani, R. A Detailed Review on Analytical Methods to Manage the Impurities in Drug Substances. OAlib 2023, 10, 1–18. [Google Scholar] [CrossRef]
  74. Mattrey, F.T.; Makarov, A.A.; Regalado, E.L.; Bernardoni, F.; Figus, M.; Hicks, M.B.; Zheng, J.; Wang, L.; Schafer, W.; Antonucci, V.; et al. Current Challenges and Future Prospects in Chromatographic Method Development for Pharmaceutical Research. TrAC-Trends Anal. Chem. 2017, 95, 36–46. [Google Scholar] [CrossRef]
  75. Dispas, A.; Sacré, P.Y.; Ziemons, E.; Hubert, P. Emerging Analytical Techniques for Pharmaceutical Quality Control: Where Are We in 2022? J. Pharm. Biomed. Anal. 2022, 221, 115071. [Google Scholar] [CrossRef] [PubMed]
  76. Maji, A.K.; Banerjee, D.; Maity, N.; Banerji, P. A Validated RP-HPLC-UV Method for Quantitative Determination of Puerarin in Pueraria tuberosa DC Tuber Extract. Pharm. Methods 2012, 3, 79–83. [Google Scholar] [CrossRef] [PubMed]
  77. Wu, X.-Y.; Yang, L.-L.; Liu-Qing, Y.; Zou, Y.-M.; Lu, J.-M. Simultaneous RP-HPLC Determination of Puerarin, Daidzin and Daidzein in Roots, Stems and Leaves of Pueraria Lobata (Wild) Ohwi. Food Sci. 2009, 30, 248–252. [Google Scholar]
  78. Chauhan, S.K.; Singh, B.; Agrawal, S. Determination of Puerarin from Pueraria tuberosa DC by Hplc. Anc. Sci. Life 2004, 23, 22–25. [Google Scholar] [PubMed]
  79. Chew, Y.L.; Khor, M.A.; Lim, Y.Y. Choices of Chromatographic Methods as Stability Indicating Assays for Pharmaceutical Products: A Review. Heliyon 2021, 7, e06553. [Google Scholar] [CrossRef] [PubMed]
  80. Yi, Y.; Adrjan, B.; Li, J.; Hu, B.; Roszak, S. NMR Studies of Daidzein and Puerarin: Active Anti-Oxidants in Traditional Chinese Medicine. J. Mol. Model. 2019, 25, 202. [Google Scholar] [CrossRef] [PubMed]
  81. Shockcor, J.P. HPLC–NMR, Pharmaceutical Applications☆. In Encyclopedia of Spectroscopy and Spectrometry, 3rd ed.; Lindon, J.C., Tranter, G.E., Koppenaal, D.W., Eds.; Academic Press: Oxford, UK, 2017; pp. 141–151. ISBN 978-0-12-803224-4. [Google Scholar]
  82. Gebretsadik, T.; Linert, W.; Thomas, M.; Berhanu, T.; Frew, R. LC–NMR for Natural Product Analysis: A Journey from an Academic Curiosity to a Robust Analytical Tool. Science 2021, 3, 6. [Google Scholar] [CrossRef]
  83. Seger, C.; Sturm, S. NMR-Based Chromatography Readouts: Indispensable Tools to “Translate” Analytical Features into Molecular Structures. Cells 2022, 11, 3526. [Google Scholar] [CrossRef]
  84. Gao, D.; Cho, C.W.; Kim, J.H.; Lee, E.J.; Kim, C.T.; Kang, J.S. A New HPLC Method for the Analysis of Puerarin for Quality Control of the Extract of Pueraria Lobate Stem and Puerarin Cream. J. Pharm. Sci. 2020, 35, 88–93. [Google Scholar]
  85. Gao, D.; Kim, J.H.; Kim, C.T.; Jeong, W.S.; Kim, H.M.; Sim, J.; Kang, J.S.; Attanzio, A. Molecular Sciences Evaluation of Anti-Melanogenesis Activity of Enriched Pueraria Lobata Stem Extracts and Characterization of Its Phytochemical Components Using HPLC-PDA-ESI-MS/MS. Int. J. Mol. Sci. 2021, 22, 8105. [Google Scholar] [CrossRef] [PubMed]
  86. Qu, L.; Song, K.; Zhang, Q.; Guo, J.; Huang, J. Simultaneous Determination of Six Isoflavones from Puerariae Lobatae Radix by CPE-HPLC and Effect of Puerarin on Tyrosinase Activity. Molecules 2020, 25, 344. [Google Scholar] [CrossRef]
  87. Shang, X.; Huang, D.; Wang, Y.; Xiao, L.; Ming, R.; Zeng, W.; Cao, S.; Lu, L.; Wu, Z.; Yan, H. Identification of Nutritional Ingredients and Medicinal Components of Pueraria Lobata and Its Varieties Using Uplc-Ms/Ms-Based Metabolomics. Molecules 2021, 26, 6587. [Google Scholar] [CrossRef] [PubMed]
  88. Jin, L.; Li, X.; Chen, X.; Chen, X.; Liu, Y.; Xu, H.; Wang, Q.; Tang, Z. A Study on Puerarin in Situ Gel Eye Drops: Formulation Optimization and Pharmacokinetics on Rabbits by Microdialysis. Int. J. Pharm. 2023, 642, 123176. [Google Scholar] [CrossRef]
  89. Yang, K.; Zhang, X.; Liu, D.; Wen, S.; Wu, Y.; Li, T.; Tang, T.; Wang, Y.; Zou, T.; Zhao, C.; et al. Water Extracts of Pueraria Thomsonii Radix Ameliorates Alcoholic Liver Disease via PI3K/AKT and NOX4/ROS Pathways. J. Funct. Foods 2023, 110, 105830. [Google Scholar] [CrossRef]
  90. Baranyika, J.B.; Bakire, S.; Shoucheng, P.; Meihao, S.; Hirwa, H. Application of the Selected Macroporous Resin for the Separation and Identification of Flavonoids from Chinese Radix Pueraria Lobata by HPLC-Q-TOF-MS. Microchem. J. 2024, 196, 109662. [Google Scholar] [CrossRef]
  91. Zheng, Y.; Ren, W.; Zhang, L.; Zhang, Y.; Liu, D.; Liu, Y. A Review of the Pharmacological Action of Astragalus Polysaccharide. Front. Pharmacol. 2020, 11, 349. [Google Scholar] [CrossRef]
  92. Li, Z.; Wang, Y.; Xu, Q.; Ma, J.; Li, X.; Tian, Y.; Wen, Y.; Chen, T. Ginseng and Health Outcomes: An Umbrella Review. Front. Pharmacol. 2023, 14, 1069268. [Google Scholar] [CrossRef]
  93. Akaberi, M.; Baharara, H.; Amiri, M.S.; Moghadam, A.T.; Sahebkar, A.; Emami, S.A. Ginkgo Biloba: An Updated Review on Pharmacological, Ethnobotanical, and Phytochemical Studies. Pharmacol. Res.-Mod. Chin. Med. 2023, 9, 100331. [Google Scholar] [CrossRef]
  94. Wang, L.; Liang, Q.; Lin, A.; Chen, X.; Wu, Y.; Zhang, B.; Zhang, Y.; Min, H.; Wen, Y.; Song, S.; et al. Puerarin Increases Survival and Protects Against Organ Injury by Suppressing NF-ΚB/JNK Signaling in Experimental Sepsis. Front. Pharmacol. 2020, 11, 560. [Google Scholar] [CrossRef] [PubMed]
  95. Zeng, X.P.; Zeng, J.H.; Lin, X.; Ni, Y.H.; Jiang, C.S.; Li, D.Z.; He, X.J.; Wang, R.; Wang, W. Puerarin Ameliorates Caerulein-Induced Chronic Pancreatitis via Inhibition of MAPK Signaling Pathway. Front. Pharmacol. 2021, 12, 686992. [Google Scholar] [CrossRef] [PubMed]
  96. Wang, D.; Bu, T.; Li, Y.; He, Y.; Yang, F.; Zou, L. Pharmacological Activity, Pharmacokinetics, and Clinical Research Progress of Puerarin. Antioxidants 2022, 11, 2121. [Google Scholar] [CrossRef] [PubMed]
  97. Bai, Y.L.; Han, L.L.; Qian, J.H.; Wang, H.Z. Molecular Mechanism of Puerarin Against Diabetes and Its Complications. Front. Pharmacol. 2022, 12, 780419. [Google Scholar] [CrossRef] [PubMed]
  98. Shao, M.; Ye, C.; Bayliss, G.; Zhuang, S. New Insights Into the Effects of Individual Chinese Herbal Medicines on Chronic Kidney Disease. Front. Pharmacol. 2021, 12, 774414. [Google Scholar] [CrossRef] [PubMed]
  99. Tang, F.; Yan, H.L.; Wang, L.X.; Xu, J.F.; Peng, C.; Ao, H.; Tan, Y.Z. Review of Natural Resources with Vasodilation: Traditional Medicinal Plants, Natural Products, and Their Mechanism and Clinical Efficacy. Front. Pharmacol. 2021, 12, 627458. [Google Scholar] [CrossRef] [PubMed]
  100. Zhou, Y.X.; Zhang, H.; Peng, C. Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases. Front. Pharmacol. 2021, 12, 771793. [Google Scholar] [CrossRef] [PubMed]
  101. Li, Z.; Fan, Y.; Huang, C.; Liu, Q.; Huang, M.; Chen, B.; Peng, Z.; Zhu, W.; Ding, B. Efficacy and Safety of Puerarin Injection on Acute Heart Failure: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2022, 9, 934598. [Google Scholar] [CrossRef] [PubMed]
  102. Xu, H.; Yu, S.; Lin, C.; Dong, D.; Xiao, J.; Ye, Y.; Wang, M. Roles of Flavonoids in Ischemic Heart Disease: Cardioprotective Effects and Mechanisms against Myocardial Ischemia and Reperfusion Injury. Phytomedicine 2024, 126, 155409. [Google Scholar] [CrossRef] [PubMed]
  103. Li, R.; Liang, T.; He, Q.; Guo, C.; Xu, L.; Zhang, K.; Duan, X. Puerarin, Isolated from Kudzu Root (Willd.), Attenuates Hepatocellular Cytotoxicity and Regulates the GSK-3β/NF-ΚB Pathway for Exerting the Hepatoprotection against Chronic Alcohol-Induced Liver Injury in Rats. Int. Immunopharmacol. 2013, 17, 71–78. [Google Scholar] [CrossRef]
  104. Liu, Y.S.; Yuan, M.H.; Zhang, C.Y.; Liu, H.M.; Liu, J.R.; Wei, A.L.; Ye, Q.; Zeng, B.; Li, M.F.; Guo, Y.P.; et al. Puerariae Lobatae Radix Flavonoids and Puerarin Alleviate Alcoholic Liver Injury in Zebrafish by Regulating Alcohol and Lipid Metabolism. Biomed. Pharmacother. 2021, 134, 111121. [Google Scholar] [CrossRef] [PubMed]
  105. Yang, M.; Xia, L.; Song, J.; Hu, H.; Zang, N.; Yang, J.; Zou, Y.; Wang, L.; Zheng, X.; He, Q.; et al. Puerarin Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease by Inhibiting Ferroptosis and Inflammation. Lipids Health Dis. 2023, 22, 202. [Google Scholar] [CrossRef] [PubMed]
  106. Xiao, B.; Sun, Z.; Cao, F.; Wang, L.; Liao, Y.; Liu, X.; Pan, R.; Chang, Q. Brain Pharmacokinetics and the Pharmacological Effects on Striatal Neurotransmitter Levels of Pueraria Lobata Isoflavonoids in Rat. Front. Pharmacol. 2017, 8, 599. [Google Scholar] [CrossRef] [PubMed]
  107. Gao, M.; Zhang, Z.; Lai, K.; Deng, Y.; Zhao, C.; Lu, Z.; Geng, Q. Puerarin: A Protective Drug against Ischemia-Reperfusion Injury. Front. Pharmacol. 2022, 13, 927611. [Google Scholar] [CrossRef] [PubMed]
  108. Liang, W.; Li, X.; Wang, H.; Nie, K.; Meng, Q.; He, J.; Zheng, C. Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection. Front. Immunol. 2022, 13, 892350. [Google Scholar] [CrossRef] [PubMed]
  109. Lv, J.; Shi, S.; Zhang, B.; Xu, X.; Zheng, H.; Li, Y.; Cui, X.; Wu, H.; Song, Q. Role of Puerarin in Pathological Cardiac Remodeling: A Review. Pharmacol. Res. 2022, 178, 106152. [Google Scholar] [CrossRef] [PubMed]
  110. Jiang, Z.; Cui, X.; Qu, P.; Shang, C.; Xiang, M.; Wang, J. Roles and Mechanisms of Puerarin on Cardiovascular Disease: A Review. Biomed. Pharmacother. 2022, 147, 112655. [Google Scholar] [CrossRef] [PubMed]
  111. Yan, J.; Honglei, Y.; Yun, W.; Sheng, D.; Yun, H.; Anhua, Z.; Na, F.; Min, L.; Dandan, S.; Jing, W.; et al. Puerarin Ameliorates Myocardial Remodeling of Spontaneously Hypertensive Rats through Inhibiting TRPC6-CaN-NFATc3 Pathway. Eur. J. Pharmacol. 2022, 933, 175254. [Google Scholar] [CrossRef] [PubMed]
  112. Qin, W.; Guo, J.; Gou, W.; Wu, S.; Guo, N.; Zhao, Y.; Hou, W. Molecular Mechanisms of Isoflavone Puerarin against Cardiovascular Diseases: What We Know and Where We Go. Chin. Herb. Med. 2022, 14, 234–243. [Google Scholar] [CrossRef]
  113. Peng, Y.; Wang, L.; Zhao, X.; Lai, S.; He, X.; Fan, Q.; He, H.; He, M. Puerarin Attenuates Lipopolysaccharide-Induced Myocardial Injury via the 14-3-3γ/PKCε Pathway Activating Adaptive Autophagy. Int. Immunopharmacol. 2022, 108, 108905. [Google Scholar] [CrossRef]
  114. Peng, Y.; Wang, L.; Zhang, Z.; He, X.; Fan, Q.; Cheng, X.; Qiao, Y.; Huang, H.; Lai, S.; Wan, Q.; et al. Puerarin Activates Adaptive Autophagy and Protects the Myocardium against Doxorubicin-Induced Cardiotoxicity via the 14–3-3γ/PKCε Pathway. Biomed. Pharmacother. 2022, 153, 113403. [Google Scholar] [CrossRef] [PubMed]
  115. Xu, J.; Tian, Z.; Li, Z.; Du, X.; Cui, Y.; Wang, J.; Gao, M.; Hou, Y. Puerarin-Tanshinone IIA Suppresses Atherosclerosis Inflammatory Plaque via Targeting Succinate/HIF-1α/IL-1β Axis. J. Ethnopharmacol. 2023, 317, 116675. [Google Scholar] [CrossRef] [PubMed]
  116. Hao, R.; Ge, J.; Li, F.; Jiang, Y.; Sun-Waterhouse, D.; Li, D. MiR-34a-5p/Sirt1 Axis: A Novel Pathway for Puerarin-Mediated Hepatoprotection against Benzo(a)Pyrene. Free Radic. Biol. Med. 2022, 186, 53–65. [Google Scholar] [CrossRef] [PubMed]
  117. Keskin Alkaç, Z.; Ahmet Korkak, F.; Dağoğlu, G.; Akdeniz İncili, C.; Dağoğlu Hark, B.; Tanyıldızı, S. Puerarin Mitigates Oxidative Injuries, Opening of Mitochondrial Permeability Transition Pores and Pathological Damage Associated with Liver and Kidney in Xanthium Strumarium-Intoxicated Rats. Toxicon 2022, 213, 13–22. [Google Scholar] [CrossRef] [PubMed]
  118. HU, Y.; WANG, S.; WU, L.; YANG, K.; YANG, F.; YANG, J.; HU, S.; YAO, Y.; XIA, X.; LIU, Y.; et al. Puerarin Inhibits Inflammation and Lipid Accumulation in Alcoholic Liver Disease through Regulating MMP8. Chin. J. Nat. Med. 2023, 21, 670–681. [Google Scholar] [CrossRef] [PubMed]
  119. Xu, B.; Wang, H.; Chen, Z. Puerarin Inhibits Ferroptosis and Inflammation of Lung Injury Caused by Sepsis in LPS Induced Lung Epithelial Cells. Front. Pediatr. 2021, 9, 706327. [Google Scholar] [CrossRef] [PubMed]
  120. Zhang, P.; Zhang, Y.; Wang, L.; Wang, X.; Xu, S.; Zhai, Z.; Wang, C.; Cai, H. Reversal of NADPH Oxidase-Dependent Early Oxidative and Inflammatory Responses in Chronic Obstructive Pulmonary Disease by Puerarin. Oxid. Med. Cell Longev. 2022, 2022, 5595781. [Google Scholar] [CrossRef] [PubMed]
  121. Peng, Z.T.; Liu, H. Puerarin Attenuates LPS-Induced Inflammatory Injury in Gastric Epithelial Cells by Repressing NLRP3 Inflammasome-Mediated Apoptosis. Toxicol. In Vitro 2022, 81, 105350. [Google Scholar] [CrossRef] [PubMed]
  122. Li, X.; Wang, J.; Yan, J.; He, J.C.; Li, Y.; Zhong, Y. Additive Renal Protective Effects between Arctigenin and Puerarin in Diabetic Kidney Disease. Biomed. Pharmacother. 2024, 171, 116107. [Google Scholar] [CrossRef]
  123. Hou, B.; Ma, P.; Yang, X.; Zhao, X.; Zhang, L.; Zhao, Y.; He, P.; Du, G.; Qiang, G. In Silico Prediction and Experimental Validation to Reveal the Protective Mechanism of Puerarin against Excessive Extracellular Matrix Accumulation through Inhibiting Ferroptosis in Diabetic Nephropathy. J. Ethnopharmacol. 2024, 319, 117281. [Google Scholar] [CrossRef]
  124. Zeng, X.; Chen, B.; Wang, L.; Sun, Y.; Jin, Z.; Liu, X.; Ouyang, L.; Liao, Y. Chitosan@Puerarin Hydrogel for Accelerated Wound Healing in Diabetic Subjects by MiR-29ab1 Mediated Inflammatory Axis Suppression. Bioact. Mater. 2023, 19, 653–665. [Google Scholar] [CrossRef]
  125. Song, X.; Wang, W.; Ding, S.; Wang, Y.; Ye, L.; Chen, X.; Ma, H. Exploring the Potential Antidepressant Mechanisms of Puerarin: Anti-Inflammatory Response via the Gut-Brain Axis. J. Affect. Disord. 2022, 310, 459–471. [Google Scholar] [CrossRef] [PubMed]
  126. Liu, X.; Sui, X.; Zhang, Y.; Yue, R.; Yin, S. Efficacy of Puerarin in Rats with Focal Cerebral Ischemia through Modulation of the SIRT1/HIF-1α/VEGF Signaling Pathway and Its Effect on Synaptic Plasticity. Heliyon 2023, 9, e15872. [Google Scholar] [CrossRef] [PubMed]
  127. Liu, X.; Huang, R.; Wan, J. Puerarin: A Potential Natural Neuroprotective Agent for Neurological Disorders. Biomed. Pharmacother. 2023, 162, 114581. [Google Scholar] [CrossRef] [PubMed]
  128. Lin, S.P.; Zhu, L.; Shi, H.; Ye, S.; Li, Q.; Yin, X.; Xie, Q.; Xu, Q.; Wei, J.X.; Mei, F.; et al. Puerarin Prevents Sepsis-Associated Encephalopathy by Regulating the AKT1 Pathway in Microglia. Phytomedicine 2023, 121, 155119. [Google Scholar] [CrossRef]
  129. Zhou, S.; Li, Y.; Hong, Y.; Zhong, Z.; Zhao, M. Puerarin Protects against Sepsis-Associated Encephalopathy by Inhibiting NLRP3/Caspase-1/GSDMD Pyroptosis Pathway and Reducing Blood-Brain Barrier Damage. Eur. J. Pharmacol. 2023, 945, 175616. [Google Scholar] [CrossRef]
  130. Liu, T.; Su, K.; Cai, W.; Ao, H.; Li, M. Therapeutic Potential of Puerarin against Cerebral Diseases: From Bench to Bedside. Eur. J. Pharmacol. 2023, 953, 175695. [Google Scholar] [CrossRef]
  131. Chen, H.; Hu, X.; Lan, Y.; Chen, S.; Xiang, X.; Tan, Y.; Zeng, G.; Guo, Z.; Li, K.; Zhang, J. Puerarin Promotes Apoptosis and Senescence of Bladder Cancer Cells. J. Funct. Foods 2022, 91, 105032. [Google Scholar] [CrossRef]
  132. Ma, R.; Zhao, L.; Zhao, Y.; Li, Y. Puerarin Action on Stem Cell Proliferation, Differentiation and Apoptosis: Therapeutic Implications for Geriatric Diseases. Phytomedicine 2022, 96, 153915. [Google Scholar] [CrossRef]
  133. Li, T.; Shi, C.; Mi, Z.; Xu, H.; Xu, J.; Wang, L.; Zhang, X. Biocompatible Puerarin Injectable-Hydrogel Using Self-Assembly Tetrapeptide for Local Treatment of Osteoarthritis in Rats. J. Drug Deliv. Sci. Technol. 2022, 78, 103909. [Google Scholar] [CrossRef]
  134. Qiu, Z.; Li, L.; Huang, Y.; Shi, K.; Zhang, L.; Huang, C.; Liang, J.; Zeng, Q.; Wang, J.; He, X.; et al. Puerarin Specifically Disrupts Osteoclast Activation via Blocking Integrin-Β3 Pyk2/Src/Cbl Signaling Pathway. J. Orthop. Translat 2022, 33, 55–69. [Google Scholar] [CrossRef] [PubMed]
  135. Li, B.; Wang, Y.; Gong, S.; Yao, W.; Gao, H.; Liu, M.; Wei, M. Puerarin Improves OVX-Induced Osteoporosis by Regulating Phospholipid Metabolism and Biosynthesis of Unsaturated Fatty Acids Based on Serum Metabolomics. Phytomedicine 2022, 102, 154198. [Google Scholar] [CrossRef] [PubMed]
  136. Huang, W.; Guo, Y.; Han, X.; Xie, X. Effect and Mechanisms of Puerarin on the Treatment of Postmenopausal Osteoporosis: A Preliminary Pre-Clinical Study. Asian J. Surg. 2023, 46, 1332–1333. [Google Scholar] [CrossRef] [PubMed]
  137. Meng, F.; Guo, B.; Ma, Y.-q.; Li, K.-w.; Niu, F.-j. Puerarin: A Review of Its Mechanisms of Action and Clinical Studies in Ophthalmology. Phytomedicine 2022, 107, 154465. [Google Scholar]
  138. Dong, Y.; Ding, Y.Y.; Gao, W.P. Puerarin Alleviates Hyperosmotic Stress-Induced Oxidative Stress, Inflammation, Apoptosis and Barrier Damage of Human Corneal Epithelial Cells by Targeting SIRT1/NLRP3 Signaling. Toxicol. In Vitro 2024, 94, 105722. [Google Scholar] [CrossRef]
  139. Xu, B.; Li, J.; Chen, X.; Kou, M. Puerarin Attenuates Cisplatin-Induced Apoptosis of Hair Cells through the Mitochondrial Apoptotic Pathway. Biochim. Biophys. Acta Mol. Cell Res. 2022, 1869, 119208. [Google Scholar] [CrossRef] [PubMed]
  140. He, L.; Wu, X.; Zhang, X.; Li, X.; Lin, X.; Huang, Y.; Wu, J. Puerarin Protects against H2O2-Induced Apoptosis of HTR-8/SVneo Cells by Regulating the MiR-20a-5p/VEGFA/Akt Axis. Placenta 2022, 126, 202–208. [Google Scholar] [CrossRef]
  141. Wu, S.; Snajdrova, R.; Moore, J.C.; Baldenius, K.; Bornscheuer, U.T. Biocatalysis: Enzymatic Synthesis for Industrial Applications. Angew. Chem. Int. Ed. 2021, 60, 88–119. [Google Scholar] [CrossRef]
  142. Scherer, M.; Fleishman, S.J.; Jones, P.R.; Dandekar, T.; Bencurova, E. Computational Enzyme Engineering Pipelines for Optimized Production of Renewable Chemicals. Front. Bioeng. Biotechnol. 2021, 9, 673005. [Google Scholar] [CrossRef]
  143. Nam, K.; Shao, Y.; Major, D.T.; Wolf-Watz, M. Perspectives on Computational Enzyme Modeling: From Mechanisms to Design and Drug Development. ACS Omega 2024, 9, 7393–7412. [Google Scholar] [CrossRef]
  144. Dobrzynska, M.; Napierala, M.; Florek, E. Flavonoid Nanoparticles: A Promising Approach for Cancer Therapy. Biomolecules 2020, 10, 1268. [Google Scholar] [CrossRef] [PubMed]
  145. Liga, S.; Paul, C.; Moacă, E.A.; Péter, F. Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy. Pharmaceutics 2024, 16, 223. [Google Scholar] [CrossRef] [PubMed]
  146. Ranjbar, S.; Emamjomeh, A.; Sharifi, F.; Zarepour, A.; Aghaabbasi, K.; Dehshahri, A.; Sepahvand, A.M.; Zarrabi, A.; Beyzaei, H.; Zahedi, M.M.; et al. Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles. Pharmaceutics 2023, 15, 1944. [Google Scholar] [CrossRef] [PubMed]
  147. Chen, T.; Liu, W.; Xiong, S.; Li, D.; Fang, S.; Wu, Z.; Wang, Q.; Chen, X. Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson’s Disease. ACS Appl. Mater. Interfaces 2019, 11, 45276–45289. [Google Scholar] [CrossRef] [PubMed]
  148. Yan, J.; Guan, Z.Y.; Zhu, W.F.; Zhong, L.Y.; Qiu, Z.Q.; Yue, P.F.; Wu, W.T.; Liu, J.; Huang, X. Preparation of Puerarin Chitosan Oral Nanoparticles by Ionic Gelation Method and Its Related Kinetics. Pharmaceutics 2020, 12, 216. [Google Scholar] [CrossRef] [PubMed]
  149. Han, Q.; Chen, K.; Su, C.; Liu, X.; Luo, X. Puerarin Loaded PLGA Nanoparticles: Optimization Processes of Preparation and Anti-Alcohol Intoxication Effects in Mice. AAPS PharmSciTech 2021, 22, 217. [Google Scholar] [CrossRef]
  150. Qiang, S.; Gu, L.; Kuang, Y.; Zhao, M.; You, Y.; Han, Q. Changes in the Content of Puerarin-PLGA Nanoparticles in Mice under the Influence of Alcohol and Analysis of Their Antialcoholism. J. Appl. Biomater. Funct. Mater. 2023, 21, 22808000221148100. [Google Scholar] [CrossRef]
Figure 1. A schematic illustration of the basic structure, natural sources, and biological effects of flavonoids, including the most common isoflavones.
Figure 1. A schematic illustration of the basic structure, natural sources, and biological effects of flavonoids, including the most common isoflavones.
Ijms 25 05222 g001
Figure 2. Chemical structure of puerarin.
Figure 2. Chemical structure of puerarin.
Ijms 25 05222 g002
Figure 3. Overview of the main steps of the puerarin biosynthesis pathway.
Figure 3. Overview of the main steps of the puerarin biosynthesis pathway.
Ijms 25 05222 g003
Table 1. Advantages and disadvantages of various techniques for extracting puerarin from natural sources.
Table 1. Advantages and disadvantages of various techniques for extracting puerarin from natural sources.
Extraction
Techniques
AdvantagesDisadvantagesReferences
Traditional
(e.g., Maceration,
Percolation,
Decoction, Soxhlet)
Low installation cost
Low maintenance cost
Dynamic extraction
  • Time-consuming process
  • Poor purity
  • Low efficiency
  • Large amounts of potentially toxic solvents
  • Significant waste production
  • Difficulty with automation
[47,48,53]
Microwave-Assisted Extraction
Shorter time
Higher extraction rate
Low consumption of organic solvents
Lower costs
Low pollution
  • Generating free radicals
  • Heating occurs during extraction
  • Restricted to polar solvents
  • Not specifically for volatile solvents
[46,47,48,53,54,55,56]
Ultrasound-Assisted Extraction
Heating is not necessary
High efficiency and yields
Low energy consumption
Less solvent
  • Excessive ultrasonic energy may lead to degradation of puerarin
[47,48,53,57,58,59,60]
Supercritical Fluid
Extraction
Environmentally friendly
High selectivity
Mild extraction conditions
Requires less energy and resources
  • Limited mass transfer
  • Expensive equipment
  • Required technical knowledge of different specific properties
[46,47,48,61,62]
Enzyme-Assisted
Extraction
Gentle reaction conditions
Eco-friendly extraction solvents
Minimal active substance loss
Mild conditions
Higher extraction rate
Possibility of combining with various extraction methods (e.g., ultrasound-assisted extraction, microwave-assisted extraction)
  • High cost of enzymes
[46,47,48,63]
Deep Eutectic
Solvents
Extraction
Green solvents
DES are extremely easy to prepare with high purity
Lower extraction temperature
Lower costs
Shorter extraction time
High selectivity
  • Limited mass transfer
  • High density and viscosity
  • Low vapor pressure
[64,65,66,67]
Table 2. Details of various analytical methods used for the estimation of puerarin.
Table 2. Details of various analytical methods used for the estimation of puerarin.
AnalyteColumn; Mobile PhaseFlow Rate; Temperature; Detection WavelengthCombined Technique
Parameters
ResultsReferences
Puerarin
(Pueraria lobata
stem extract,
puerarin cream)
Optimapark C18 column
(250 × 4.6 mm, 5 μm);
A: 0.5% aqueous acetic acid;
B: methanol
(77:23, v/v)
1 mL/min; 30 °C;
250 nm
-
  • Retention time = 10.75 min;
  • Total analysis time = 25 min;
  • Puerarin content in extract (0.29 ± 0.01%); puerarin content cream (0.015 ± 0.001%);
  • This analytical method was successfully applied to quality control of raw material and cosmetic product.
[84]
Puerarin
(Pueraria lobata)
Optimapark C18 column
(4.6 mm × 250 mm, 5 μm);
A: 0.1% formic acid/aqueous solution;
B: acetonitrile
1 mL/minPDA–ESI–MS/MS:
Detection: 200 ÷ 400 nm;
Drying gas flow: 15 L/min;
Nebulizing gas flow rate: 3 L/min;
Desolvation line temperature: 250 °C;
Heat block temperature: 400 °C.
  • Retention time = 15.43 min;
  • [M+H]+ = 417.10;
  • [M−H] = 415.09;
  • Product ion (m/z) = 297.12;
  • λ Max (nm) = 250, 305.
[85]
Puerarin
(Pueraria lobata
radix)
ZORBAX SB C18 reversed-phase column
(4.6 mm × 250 mm, 5 μm);
A: 0.2% phosphoric acid/
water;
B: methanol
1 mL/min; 35 °C;
475 nm
-
  • Precision (RSD) = 0.40–1.63%;
  • Stability (RSD) = 1.05–4.95%;
  • Repeatability (RSD) = 2.52–4.95%;
  • LODs = 0.0152–0.0307 μg/mL;
  • LOQs = 0.0506–0.1024 μg/mL;
  • The maximum extraction efficiency reached 8.92 mg/g with 7.66 mg/g puerarin.
[86]
Puerarin
(Pueraria lobata)
Agilent SB-C18
(2.1 mm × 100 mm, 1.8 μm);
A: water/0.1% formic acid;
B: acetonitrile/0.1% formic acid
40 °CESI–(QTRAP)–MS:
Source temperature: 550 °C;
Ion spray voltage (IS): 5500 V (positive ion mode)/−4500 V (negative ion mode);
Source: gas I, gas II, and curtain gas (50, 60, and 25.0 psi).
  • Retention time = 3.22 min;
  • [M+H]+ = 417.
[87]
Puerarin
(gel eye drops)
Agilent Zorbax SB-C18 column
(3.0 × 150 mm, 3.5 μm);
A: acetonitrile gradient;
B: 0.1% formic acid
(15:85, v:v)
0.6 mL/min; 35 °C;
250 nm
MS:
Nebulizing gas: 55 psi;
Turbo ion spray
temperature = 600 °C;
Collision gas = 8 psi;
Curtain gas = 20 psi;
Ion spray
voltage: −4500 V.
  • Product ion (m/z) = 415.1;
  • The declustering potential is −80 V, entrance potential is −10 V, collision energy is −45 V, and collision cell exit potential is −10 V;
  • Three levels of quality control samples (LQC 6 ng/mL, MQC 150 ng/mL, and HQC 3200 ng/mL) as well as LLOQ (2 ng/mL);
  • The RSDs were below 10% for intra- and inter-day precision measurements, and the accuracy ranged from 92.3 to 104.0%, suggesting their analytical approach was reliable and acceptable for quantifying PUE in aqueous humor.
[88]
Puerarin
(Pueraria
thomsonii
radix)
Waters BEH C18 column
(2.1 mm × 100 mm, 1.7 μm);
A: 0.1% formic acid/water;
B: 0.1% formic acid/acetonitrile
0.3 mL/min; 30 °CQ-TOF-MS:
Range (m/z): 100–2000;
Source voltages of 5500 V (positive ion) and −4500 V (negative ion);
Ion source temperatures = 600 °C and 500 °C;
Cracking voltage (±80 V);
Collision energy (±10 eV).
  • Selected ion: [M−H];
  • Retention time = 5.14 min;
  • Calculated and measured mass = 415.1036;
  • RSD = 0.73%;
  • Reproducibility (RSD) = 0.15%;
  • The extract contained 2.1145 mg/mL puerarin.
[89]
Puerarin
(Pueraria
tuberosa)
C18
(250 mm × 4.6 mm);
A: methanol;
B: water
(25:27 ratio)
1 mL/min; 25 °C;
250 nm
Q-TOF-MS
  • Retention time = 18.156 min;
  • [M+H]+ = 417.1201;
  • [M+Na]+ = 439.1015.
[90]
Table 3. Summary of the various biological effects of puerarin.
Table 3. Summary of the various biological effects of puerarin.
Type of Disease/DisorderBiological Effects of PuerarinReferences
Cardiovascular
disease
Inhibits or regulates critical molecular activities involved in the major cellular events of cardiac remodeling, such as JNK1/2, AMPK/mTOR, PPAR α/γ, Na+/K+-ATPase, HIF-1 α, angiopoietin, and myocardial death-related pathways (e.g., mitochondrial apoptosis, necrosis, autophagy);
Relieves the effects of oxidative stress and inflammation;
Improves mitochondrial function;
Decreases the death of cardiomyocytes.
[109]
Alleviates hyperpermeability by decreasing the levels of TNF-α and IL-1β;
Inhibits the expression of adhesion molecules, and the inflammatory factors IL-8, COX-2, IL-1β, TNF-α, and IL-6 to exert an anti-inflammatory effect in atherosclerosis;
Improves the lipid profile by reducing the levels of blood triglyceride, total cholesterol, and low-density lipoprotein cholesterol;
Increases the levels of high-density lipoprotein cholesterol in hyperlipidemic rats;
Improves regulation of Na+/K+-ATPase;
Decreases inflammation, oxidative stress, autophagy, and myocardial fibrosis.
[110]
Reduces myocardial remodeling-related proteins expression;
Attenuates reactive oxygen species, restores mitochondrial membrane potential, and decreases Ca2+-overload in vitro.
[111]
Anti-myocardial fibrosis and anti-myocardial ischemia effects;
Inhibits myocardial hypertrophy;
Anti-atherosclerosis effects;
Inhibits the activation of p38-MAPK and reduces the content of TNF-a in serum;
Inhibits the activity of myeloperoxidase and decreases malondialdehyde content in the myocardial tissue;
Lowers blood pressure and enhances vascular endothelial function by relaxing blood vessels through the eNOS signaling pathway.
[112]
Inhibits excess oxidative stress and the release of inflammatory cytokines;
Maintains mitochondrial function;
Promotes adaptive autophagy and protects against myocardial damage.
[113]
Puerarin pretreatment reduces the cardiotoxicity injury associated with doxorubicin, resulting in increased cell viability, decreased LDH activity, and apoptosis;
Prevents excess oxidative stress, maintains mitochondrial function and energy metabolism, and enhances myocardial function.
[114]
The reduction of IL-1β was positively correlated with succinate in the serum of puerarin–tanshinone IIA-treated mice;
Inhibits inflammation by targeting HIF-1α to interfere with the succinate signaling axis;
The combination of puerarin–tanshinone IIA was more effective in restraining inflammatory responses and the formation of atherosclerotic plaque.
[115]
Liver disease
Hepatoprotective effects against benzo[a]pyrene-induced liver damage via inhibiting oxidative stress and inflammation.
[116]
Inhibits mPTP opening, and decreases mitochondrial Ca2+ levels and ATP synthase expression;
Corrects the pathological damage caused by Xanthium strumarium toxicity.
[117]
Attenuates EtOH-induced liver injury;
Inhibits levels of SREBP-1c, TNF-α, IL-6 and IL-1β, compared with silymarin;
Acts as an inhibitor of MMP8 to reduce inflammation and lipid deposition in alcoholic-liver disease.
[118]
Respiratory
disease
Inhibits the inflammatory response to prevent LPS-induced acute lung injury;
Reduces LPS-induced damage to A549 cells;
Reduces the expression of the inflammatory cytokines TNF-α, IL-8, and IL-1β in LPS-induced A549 cells;
Improves sepsis-induced lung injury by inhibiting ferroptosis.
[119]
Redox-sensitive attenuation effect of inflammatory responses in mice exposed to ACS- and CSE-stimulated HSAECs, via inhibition of NOX-isoforms;
Reduces the production of reactive oxygen species, lowers the infiltration of inflammatory cells, and decreases the expression of inflammatory mediators.
[120]
Gastric disease
Decreases NLRP3 inflammasome-mediated injury by inducing AMPK/SIRT1 signaling in the gastric epithelium;
Protects GES-1 cells against LPS-induced injury by inhibiting NLRP3.
[121]
Kidney disease
Reduces p65 acetylation via Sirt1 activation;
Additive inhibitory effects on the NF-κB activation.
[122]
Improves glucose level and lipid metabolism;
Suppresses the production of reactive oxygen species and the accumulation of excessive collagen fiber in glomerular mesangial cells;
Downregulates TGF-β and mesenchymal transition markers in high glucose-injured glomerular mesangial cells and diabetic kidney.
[123]
Metabolic disease
The synthesis of the chitosan–puerarin hydrogel led to the discovery that it promotes diabetic wound healing by inhibiting ectopic miR-29ab1-mediated macrophages and controlling inflammation.
[124]
Neurological
disorders
Significantly attenuates depression-like behaviors in rats;
Controls the imbalance of intestinal bacteria;
Inhibits inflammatory responses in the hippocampus, serum, colon, and downregulates the TLR4/NF-κB pathway.
[125]
Improves neurological impairment and forelimb motor function;
Reduces inflammatory response;
Inhibits brain edema;
Regulates synaptic plasticity.
[126]
Induces brain-derived neurotrophic factor production in astrocytes;
Promotes phosphorylation of extracellular-signal-regulated kinases;
Protects astrocytes through the PI3K/Akt- and ERK/mitogen-activated protein kinases pathway;
Increases the potential of the mitochondrial membrane;
Decreases mitochondrial reactive oxygen species;
Increases Bcl-2 and decreases Bax levels;
Suppresses caspase-3 activation;
Decreases the production of pro-inflammatory cytokines;
Inhibits inflammatory responses;
Downregulates apoptosis-associated proteins;
Reduces calcium influx.
[127]
Significantly reduces the production of inflammatory cytokines (e.g., TNF-α, IL-6) in the peripheral blood;
Exhibits inhibitory effects on the release of TNF-α and IL-6 from microglia, preventing hippocampal neuronal cell death;
Exerts anti-neuroinflammatory effect against sepsis-associated encephalopathy by modulating the AKT1 pathway in microglia.
[128]
Inhibits the level of factors related to the classical pathway of pyroptosis (e.g., NLRP3, Caspase-1, IL-1β, IL-18);
Reduces blood–brain barrier damage.
[129]
Attenuates oxidative stress and neuron apoptosis;
Enhances synaptic plasticity;
Improves cognitive function by blocking the TRPM2/NMDA receptor pathway;
Inhibits oxidative stress, apoptosis, and autophagy deficits by promoting synaptic plasticity and suppressing oxidative stress, apoptosis, and autophagy deficits.
[130]
Urologic disease
Induces proliferation inhibition, apoptosis, and senescence of bladder cancer cells in vitro;
Inhibits CCNB1 and PI3K/AKT pathways by upregulating the miR-139-5p;
Exerts oncogenic effects in bladder cancer by regulating the miR-139-5p/CCNB1 and PI3K/AKT pathways.
[131]
Geriatric disease
Reduces bone loss;
Increases bone density;
Boosts osteogenic activity;
Helps promote bone repair and remodeling, which can be beneficial after bone transplantation or in patients with osteoporosis;
Exerts inhibitory effects on the adipogenic differentiation of bone marrow mesenchymal stem cells;
Prevents alcoholic osteonecrosis;
[132]
Encapsulation of puerarin into peptide self-assembled hydrogels significantly ameliorates the progression of monoiodoacetic acid-induced osteoarthritis in rats.
[133]
Bone disease
Significantly inhibits osteoclast activation and bone resorption, without affecting osteoclastogenesis or apoptosis;
Significantly blocks c-Fos expression.
[134]
Anti-osteoporosis effect;
Reduces adipogenic differentiation and promotes osteogenic differentiation of bone mesenchymal stem cells via activating the Wnt/β-catenin pathway and inhibiting the PPARγ pathway.
[135]
Inhibits the activity and differentiation of osteoclasts;
Inhibits osteoclast differentiation through the OPG/RANK/RANKL signaling pathway.
[136]
Ophthalmology
disease
Inhibits amyloid β-induced NLRP3 inflammasome activation in retinal pigment epithelial cells via suppressing ROS-dependent oxidative and endoplasmic reticulum stresses;
Promotes the activity of superoxide dismutase, catalase, and glutathione;
Inhibits the expression of nNOS and MDA to protect against retinal damage caused by oxidative stress;
Improves micro-circulation;
Reduces blood viscosity;
Improves the reduction of intraocular pressure.
[137]
Treatment with puerarin enhances cell viability, reduces reactive oxygen species content, increases catalase and superoxide dismutase activities, and elevates the ratio of GSH/GSSG in human corneal epithelial cells;
Attenuates hyperosmotic stress-induced injury of the human corneal epithelial cell line by targeting the regulation of the SIRT1/NLRP3 signaling.
[138]
Sensorial
disorders
Anti-apoptotic effects towards ototoxic drug (e.g., cisplatin)-induced hair cell injury in vitro;
Suppression of the synthesis of reactive oxygen species;
Inhibits apoptosis, and upregulates the Akt signaling pathway.
[139]
Pregnancy-specific disorder
Protection against H2O2-induced apoptosis in HTR-8/SVneo cells by regulating the miR-20a-5p/VEGFA/Akt axis;
Reverses H2O2-induced apoptosis and metastasis inhibition in cells;
Provides some theoretical basis for exploring effective treatments for patients with preeclampsia.
[140]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liga, S.; Paul, C. Puerarin—A Promising Flavonoid: Biosynthesis, Extraction Methods, Analytical Techniques, and Biological Effects. Int. J. Mol. Sci. 2024, 25, 5222. https://doi.org/10.3390/ijms25105222

AMA Style

Liga S, Paul C. Puerarin—A Promising Flavonoid: Biosynthesis, Extraction Methods, Analytical Techniques, and Biological Effects. International Journal of Molecular Sciences. 2024; 25(10):5222. https://doi.org/10.3390/ijms25105222

Chicago/Turabian Style

Liga, Sergio, and Cristina Paul. 2024. "Puerarin—A Promising Flavonoid: Biosynthesis, Extraction Methods, Analytical Techniques, and Biological Effects" International Journal of Molecular Sciences 25, no. 10: 5222. https://doi.org/10.3390/ijms25105222

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop